Related Experiment Video

Updated: May 23, 2026

MicroRNA In situ Hybridization for Formalin Fixed Kidney Tissues
12:21

MicroRNA In situ Hybridization for Formalin Fixed Kidney Tissues

Published on: November 30, 2013

MicroRNA target site polymorphisms in the VHL-HIF1α pathway predict renal cell carcinoma risk

Hua Wei1, Hung-Lung Ke, Jie Lin

  • 1Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Molecular Carcinogenesis
|April 21, 2012
PubMed

Insights

Genetic variations in microRNA-binding sites within the VHL-HIF1α pathway influence renal cell carcinoma (RCC) risk. Specific single-nucleotide polymorphisms (SNPs) are linked to increased or decreased RCC susceptibility, aiding in early detection strategies.

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Renal cell carcinoma (RCC) is a significant cause of cancer death.
  • The VHL-HIF1α pathway plays a crucial role in cellular response to hypoxia and cancer development.
  • Understanding genetic predispositions is vital for early RCC detection and prevention.

Purpose of the Study:

  • To investigate the association between variations in microRNA (miRNA)-binding sites of VHL-HIF1α pathway genes and RCC risk.
  • To identify specific single-nucleotide polymorphisms (SNPs) that modify an individual's susceptibility to RCC.

Main Methods:

  • A case-control study was conducted with 894 RCC cases and 1,516 controls.
  • 429 miRNA-binding site SNPs in 102 pathway genes were identified.
  • 53 tagging-SNPs for 31 genes were assessed for their association with RCC risk.

Main Results:

  • Five SNPs showed a significant association with RCC risk.
  • rs743409 in MAPK1 was linked to a 10% risk reduction (OR: 0.90).
  • Cumulative analysis revealed a 2.14-fold increased risk for individuals with four or five unfavorable genotypes. High-risk combinations of SNPs in CDCP1 and DEC1 showed a 4.46-fold increased risk.

Conclusions:

  • This study provides the first evidence linking miRNA-binding site SNPs in the VHL-HIF1α pathway to RCC risk.
  • Identified genetic variants may serve as novel biomarkers for identifying individuals at high risk for RCC.
  • Early identification of high-risk individuals can facilitate timely tumor detection and improve patient outcomes.
Keywords:
VHL-HIF1α pathwaymicroRNArenal cell carcinoma

More Related Videos

Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane05:36

Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane

Published on: February 8, 2020

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Non-LTR Retrotransposons03:18

Non-LTR Retrotransposons

As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...